FRESENIUS MEDICAL CARE - FINANCIAL FIGURES 2022

WHO WE ARE

Creating a future worth living. For our patients. Worldwide. Every day.

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.9 million patients worldwide regularly undergo dialysis treatment. United by a shared purpose of creating a future worth living for chronically and critically ill patients, we care for more than 344,000 dialysis patients around the globe. Their well-being always comes first.

It is our mission to provide the best possible care for a growing number of patients sustainably in diverse health care systems. As a vertically integrated company, our portfolio encompasses a comprehensive range of high-quality health care products and services as well as various dialysis treatment options for both in-center and home dialysis.

Revenue

Continued organic growth

HEALTH CARE SERVICES

HEALTH CARE PRODUCTS

NORTH AMERICA

EUROPE, MIDDLE EAST AND AFRICA

ASIA-PACIFIC

LATIN AMERICA

2021 €17.62 BN
2022 €19.40 BN

Operating
Income

Operating income impacted by
labor and cost inflation

1At constant currency

2Special items will be provided as separate KPI to capture effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance. These items are excluded to ensure comparability of the figures presented with the Company’s financial targets which have been defined excluding special items. For FY 2022, special items included costs related to the FME25 program, the impact of the war in Ukraine, the impact of hyperinflation in Turkiye, the remeasurement effect on the fair value of the investment in Humacyte, Inc., and the net gain related to InterWell Health.

Net
Income

Results in line with expectations

1At constant currency

2Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA.

3Special items will be provided as separate KPI to capture effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance. These items are excluded to ensure comparability of the figures presented with the Company’s financial targets which have been defined excluding special items. For FY 2022, special items included costs related to the FME25 program, the impact of the war in Ukraine, the impact of hyperinflation in Turkiye, the remeasurement effect on the fair value of the investment in Humacyte, Inc., and the net gain related to InterWell Health.

Dividend

Proposal for dividend payment planned

1Planned proposal to be approved by the Annual General Meeting on May 16, 2023.

EMPLOYEES

United by a shared purpose

2020 133,129 employees
2021 130,251 employees